Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- TCRR
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Tcr2 Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 58.11M
- Ent value
- 93.84M
- Price/Sales
- -
- Price/Book
- 0.57
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 9.07%
- 1 year return
- -36.21%
- 3 year return
- -47.71%
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
TCRR does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.57 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 39.26M |
| EPS (TTM) | -4.16 |
| FCF per share (TTM) | -2.46 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -165.80M |
| Net income (TTM) | -163.10M |
| EPS (TTM) | -4.16 |
| EPS (1y forward) | -2.46 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 14.45M |
| Net receivables | 0.00 |
| Total current assets | 140.49M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 151.51M |
| Accounts payable | 6.32M |
| Short/Current long term debt | 5.98M |
| Total current liabilities | 47.47M |
| Total liabilities | 50.18M |
| Shareholder's equity | 101.33M |
| Net tangible assets | 101.33M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -110.34M |
| Capital expenditures (TTM) | 13.63M |
| Free cash flow (TTM) | -96.54M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -160.96% |
| Return on Assets | -107.65% |
| Return on Invested Capital | -155.93% |
| Cash Return on Invested Capital | -92.29% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| TCRR | S&P500 | |
| Current price drop from All-time high | -95.66% | -11.70% |
| Highest price drop | -97.56% | -56.47% |
| Date of highest drop | 22 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -54.98% | -11.07% |
| Avg time to new high | 47 days | 12 days |
| Max time to new high | 601 days | 1805 days |
COMPANY DETAILS
Marketcap
58.11M
Marketcap category
Small-cap
Description
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. Its lead product candidate is gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin-expressing solid tumors, which is in Phase 1/2 clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma and acute myeloid leukemia. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Employees
58
Website
Investor relations
-
SEC filings
CEO
Garry E. Menzel
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner